Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 12/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 12/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 12/20 | 0.40 |
| ▸ | PTGDR2 | Q9Y5Y4 | 4/20 | 0.36 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 2/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5998677 | 0.91 | HTR2A (0.40) | AURKAHTR2ASLC6A4KCNH2PTGDR2 | |
| SCHEMBL5999496 | 0.84 | HTR2A (0.60) | HTR2ASLC6A4KCNH2 | |
| SCHEMBL5999972 | 0.81 | HTR2A (0.39) | HTR2ASLC6A4KCNH2SOS1MAOB | |
| SCHEMBL5998676 | 0.76 | HTR2A (0.60) | HTR2ASLC6A4KCNH2 | |
| Formic Acid SCHEMBL6000548 | 0.74 | SLC6A4 (0.43) | HTR2ASLC6A4KCNH2PTGDR2SOS1 | |
| SCHEMBL29998365 | 0.73 | ALDH1A1 (0.49) | — | |
| SCHEMBL303218 | 0.73 | ALDH1A1 (0.49) | — | |
| SCHEMBL5497556 | 0.72 | HTR2A (0.41) | HTR2ASLC6A4KCNH2SOS1 | |
| Formic Acid SCHEMBL6000205 | 0.71 | PTGDR2 (0.37) | HTR2ASLC6A4KCNH2PTGDR2 | |
| SCHEMBL5503447 | 0.69 | HTR2A (0.41) | HTR2ASLC6A4KCNH2SOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060058361-A1 | Therapeutic diphenyl ether ligands | PFIZER INC | 2006-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058361-A1 | Therapeutic diphenyl ether ligands | HTR2B, HTR2C, HTR3B | AURKA 3704/4885HTR2A 7/4885SLC6A4 150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.